Ian M. Waxman

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.3K citations · Full text

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok et al. · Journal of Clinical Oncology · 2017 · 1.1K citations

Surgical Oncology, Immunology, Pharmacotherapy +16

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Bernard Escudier, Padmanee Sharma, David F. McDermott et al. · European Urology · 2017 · 247 citations · Full text

Checkmate 025, Urology, Prior Therapy +10